The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors

被引：0
|
作者：
George T. Grossberg
Facundo Manes
Ricardo F. Allegri
Luis Miguel Gutiérrez-Robledo
Sergio Gloger
Lei Xie
X. Daniel Jia
Vojislav Pejović
Michael L. Miller
James L. Perhach
Stephen M. Graham
机构：
[1] Saint Louis University School of Medicine,Department of Neurology and Psychiatry
[2] Instituto de Neurología Cognitiva (INECO),undefined
[3] Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI),undefined
[4] Instituto de Geriatría,undefined
[5] Institutos Nacionales de Salud de México,undefined
[6] PsicoMedica Clinical and Research Group,undefined
[7] Forest Research Institute,undefined
[8] Prescott Medical Communications Group,undefined
来源：
CNS Drugs | 2013年 / 27卷
关键词：
Memantine; Cholinesterase Inhibitor; Semantic Fluency; Verbal Fluency Test; Severe Impairment Battery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：469 / 478
页数：9
相关论文
共 50 条
  • [31] The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
    Rogers, SL
    Friedhoff, LT
    Apter, JT
    Richter, RW
    Hartford, JT
    Walshe, TM
    Baumel, B
    Linden, RD
    Kinney, FC
    Doody, RS
    Borison, RL
    Ahem, GL
    DEMENTIA, 1996, 7 (06): : 293 - 303
  • [32] Safety and Tolerability of a Once-Daily, Extended-Release Memantine Formulation (28 Mg) in Patients with Moderate to Severe Alzheimer's Disease: Results of a 52-Week Open-Label Trial
    Meyers, Barnett S.
    Lin, Min
    Graham, Stephen M.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 18 (03): : S72 - S72
  • [33] Efficacy and safety of istradefylline in moderate to severe Parkinson's disease: A phase 3, multinational, randomized, double-blind, placebo-controlled trial (i-step study)
    Isaacson, S.
    Eggert, K.
    Kumar, R.
    Stocchi, F.
    Mori, A.
    Ohta, E.
    Toyama, K.
    Spence, G.
    Clark, G.
    Cantillon, M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 351 - 352
  • [34] Safety and Tolerability of a Once-Daily, Extended-Release Memantine Formulation (28 mg) in Patients with Moderate to Severe Alzheimer's Disease: Results of a 52-Week Open-Label Trial
    Meyers, Barnett S.
    Lin, Min
    Graham, Stephen M.
    NEUROLOGY, 2010, 74 (09) : A269 - A269
  • [35] A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain
    Wen, Warren
    Sitar, Steve
    Lynch, Shau Yu
    He, Ellie
    Ripa, Steven R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (11) : 1593 - 1606
  • [36] A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
    Targan, Stephan R.
    Feagan, Brian
    Vermeire, Severine
    Panaccione, Remo
    Melmed, Gil Y.
    Landers, Carol
    Li, Dalin
    Russell, Chris
    Newmark, Richard
    Zhang, Nan
    Chon, Yun
    Hsu, Yi-Hsiang
    Lin, Shao-Lee
    Klekotka, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (11): : 1599 - 1607
  • [37] A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease
    Connelly, Peter J.
    Prentice, Neil P.
    Cousland, Gary
    Bonham, Jim
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (02) : 155 - 160
  • [38] Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study
    Amidfar, M.
    Khiabany, M.
    Kohi, A.
    Salardini, E.
    Arbabi, M.
    Azizi, M. Roohi
    Zarrindast, M. -R.
    Mohammadinejad, P.
    Zeinoddini, A.
    Akhondzadeh, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (01) : 44 - 50
  • [39] The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial
    Chen, Christopher L. H.
    Sharma, Purabi Reang
    Tan, Boon Yeow
    Low, Casuarine
    Venketasubramanian, Narayanaswamy
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) : 38 - 45
  • [40] Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial
    Moussa, Charbel
    ANNALS OF NEUROLOGY, 2020, 88 : S100 - S100
12345